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Abstract
Herpes simplex virus type-1 (HSV-1) is a common human pathogen that relies heavily on cell-to-cell spread for establishing a
lifelong latent infection. Molecular aspects of HSV-1 entry into host cells have been well studied; however, the molecular
details of the spread of the virus from cell-to-cell remain poorly understood. In the past, the role of heparan sulfate
proteoglycans (HSPG) during HSV-1 infection has focused solely on the role of HS chains as an attachment receptor for the
virus, while the core protein has been assumed to perform a passive role of only carrying the HS chains. Likewise, very little
is known about the involvement of any specific HSPGs in HSV-1 lifecycle. Here we demonstrate that a HSPG, syndecan-1,
plays an important role in HSV-1 induced membrane fusion and cell-to-cell spread. Interestingly, the functions of syndecan-
1 in fusion and spread are independent of the presence of HS on the core protein. Using a mutant CHO-K1 cell line that
lacks all glycosaminoglycans (GAGs) on its surface (CHO-745) we demonstrate that the core protein of syndecan-1 possesses
the ability to modulate membrane fusion and viral spread. Altogether, we identify a new role for syndecan-1 in HSV-1
pathogenesis and demonstrate HS-independent functions of its core protein in viral spread.
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Introduction
Herpes simplex virus type-1 (HSV-1) is a worldwide health
problem that causes a wide range of diseases. It is a leading cause
of infectious corneal blindness in the developed world and
sporadic, fatal encephalitis worldwide. The virus also causes
asymptomatic life-long infections in a majority of adult human
population and uses a clever way of spreading from cell-to-cell to
avoid detection by the host immune system [1,2,3]. Absence of an
effective vaccine or microbicide against latent or recurrent HSV,
and the fast emerging drug-resistant virus isolates highlight the
need for developing new antivirals for HSV-1 [4]. Therefore,
characterizing the molecular basis of HSV-1 entry into host cells
and the viral-cellular interactions involved in viral spread are
crucial for the development of new approaches to prevent the
infection.
HSV-1 follows different entry routes depending on the type of
the cell it infects [5,6,7]. It can fuse at the plasma membrane, enter
via endocytosis, or get captured by cells in a phagocytosis-like
manner and fuse with the phagosomal membrane [6,7,8]. Five
HSV-1 glycoproteins are known to be involved in HSV-1 entry,
and these are HSV-1 glycoproteins gB, gC, gD, gH, and gL
[5,7,8]. The glycoprotein gC is not essential for entry, and in its
absence the virus can still enter the host cell [9]. Interaction
between the viral envelope and the plasma membrane starts with
the attachment of the virus through its glycoproteins gB and gC to
heparan sulfate (HS) moieties of HS proteoglycans (HSPG) on the
surface of a host cell [10–13]. Next, a third glycoprotein, gD binds
to one of its receptors, nectin-1, herpesvirus entry mediator
(HVEM), or 3-O sulfated HS [14,15,16] to start the process of
membrane fusion and penetration. Binding of a cell surface
receptor to gD is a necessary step for entry of HSV-1. Fusion of the
viral envelope with the host cell membrane then follows with the
combined action of HSV-1 gD, gD receptor, gB, gH, gL [14], and
possibly gB receptors [17,18] and gH receptors [19].
A similar process of membrane fusion termed HSV-1 induced
cell-to-cell fusion, involving the fusion of plasma membrane of an
infected cell with that of a neighboring uninfected cell, is thought
to occur during cell-to-cell spread [8]. Upon virus entry, viral
glycoproteins are expressed on the surface of infected cells. This
allows the binding and fusion of the viral glycoproteins on the
surface of infected cells with neighboring uninfected cells, forming
syncytia [14]. Cell-to-cell fusion allows the virus spread into
surrounding cells without the need to be released outside the cell,
allowing efficient transmission and escaping the host immune
system. The spread of HSV-1 is relatively poorly understood and
virtually nothing is known about the role of HSPGs in this process.
Syndecans are single transmembranous heparan sulfate proteo-
glycans (HSPG) with the HS chains covalently attached to the
extracellular portion of the core protein [20]. Syndecans family
constitutes the most abundant HSPGs expressed on the surface of
mammalian cells [21,22,23]. Four members in the syndecan
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4). The syndecan core protein is linearly organized into three
regions: the N-terminal ectodomain that is unique for each
syndecan, conserved transmembrane domain, and the cytoplasmic
domain that consists of two conserved regions and one variable
region specific for each syndecan [20,23]. The ectodomain has HS
attachment sites. In vivo studies have shown that syndecans-1-2 and
-3 are expressed on specific cell types. For example, syndecan-1 is
expressed predominantly in epithelial and mesenchymal tissues,
syndecan -2 in cells of mesenchymal origin, neuronal and
epithelial cells, and syndecan-3 in neuronal and musculoskeletal
tissue, whereas syndecan-4 is expressed in virtually every cell type
[24,25].
Previous studies on the role of HSPG have been primarily
focused on the role of HS chains as an attachment receptor for
HSV-1, while the core protein was given a passive role of carrying
the HS moieties. However, recent work from our lab and others
[10,11] has shown that the syndecan family of HSPG is directly
involved in HSV-1 entry. The aim of this study was to investigate
the role of syndecan-1 in membrane fusion and cell-to-cell spread
of infectious virus. Using wild type CHO-K1 cells and the mutant
CHO-745 cells deficient in glycosaminoglycans (GAGs) synthesis
[26] we show that syndecan-1 is important for HSV-1 induced
membrane fusion and cell-to-cell spread of the virus in HS-
independent manner. CHO-745 cells have an inactive form of the
xylosyltransferase enzyme essential for GAG synthesis. Therefore,
these cells express only the core protein of syndecan-1 without any
of the GAGs including HS.
In addition, using plaque assays performed in methylcellulose,
which restricts virus spread through the medium allowing plaque
formation due to virus spread from cell-to-cell, we show syndecan-
19s role in HSV-1 cell-to-cell spread in human corneal epithelial
(HCE) cells, a natural target for HSV-1 infection. Evidence has
shown that syndecan-1 exhibits very strong localization within the
corneal epithelium that represents one of the major infection sites
for HSV-1 that may precede infection of other sites within the eye
[27,28,29]. We also demonstrate that the downregulation of
syndecan-1 results in fewer plaques and therefore, less infectious
virus production. Overall, our study demonstrates a new role for
syndecan-1 in HSV-1 cell-to-cell fusion and spread.
Results
Syndecan-1 downregulation does not affect cell viability
In order to understand the significance of syndecan-1 during
HSV-1 infection, three cell lines were used to examine its role in
different aspects of HSV-1 infection. The cell lines used were the
wild type Chinese hamster ovary (CHO-K1) cells, a GAG-
deficient CHO cell line (CHO-745) [30,31], and HCE cells which
are a prime target for HSV-1 infection [29]. The cell lines were
subjected to syndecan-1 overexpression or selective downregula-
tion by siRNA. While Human syndecan-1 plasmid was used to
enhance syndecan-1 production, two sets of siRNAs were used to
selectively knockdown its expression. The downregulation of
syndecan-1 in CHO-K1, CHO-745, and HCE cells was
confirmed at the protein level using Western Blot analysis.
Densitometric analysis showed that treatment with syndecan-1
specific siRNA resulted in a significant decrease (approximately
50%) in protein production, confirming the specific downregu-
lation of syndecan-1 (Fig. 1A). Increase in syndecan-1 level was
confirmed using flowcytometric analysis on CHO-K1, CHO-745,
and HCE cells, and resulted in approximately 20–25 fold
increase. Relative mean fluorescence of syndecan-1 on the
surface of CHO-K1, CHO-745, and HCE cells is shown in
Fig. 1B. To evaluate whether alterations in syndecan-1 levels
affect cell viability, an MTS assay was performed 3-days post
syndecan-1 downregulation, and 1-day post syndecan-1 overex-
pression. Neither the former nor the latter affected cell viability
compared to control cells that were either transfected with
scrambled siRNA or transfected with the control green fluo-
rescent protein (GFP) plasmid (Fig. 1C–D). These results
demonstrated that syndecan-1 downregulation and overexpres-
sion were successful in CHO-K1, CHO-745, and HCE cells, and
neither affected cell viability.
Increase in syndecan-1 level on target cells promotes,
and its loss on target cells inhibits HSV-1 induced
cell-to-cell fusion
HSV-1 induced cell-to-cell fusion can be studied by co-
cultivating two populations of cells: ‘‘Target’’ and ‘‘Effector’’ cell
populations. Target cells express gD receptor and the luciferase
reporter gene under the control of T7 promoter. Effector cells
express HSV-1 glycoproteins that are absolutely required for virus
fusion (gB, gD, gH, and gL) plus T7 polymerase [30]. Luciferase
reporter gene activity is determined 16 h post mixing the two
populations to quantify cell-to-cell fusion. As a negative control,
target cells are mixed with effector cells that lack HSV-1 gB,
where cell-to-cell fusion is expected to be reduced dramatically
because of the absence of one of the four absolutely required HSV-
1 glycoproteins for cell-to-cell fusion; gB (Fig. 2A). Using this co-
cultivating system, we aimed to understand the contribution of the
core protein of syndecan-1 during HSV-1 induced cell-to-cell
fusion. Two cell lines were used, the wild type CHO-K1 and a
GAG-deficient CHO cell line CHO-745 that has an inactive form
of xylosyltransferase enzyme, which is required for the initiation of
GAG chain by transferring xylose to the GAG core protein
[30,31]. We have previously shown that HS plays negative role in
cell fusion; as cell-to-cell fusion increases in the absence of HS on
the cell surface [26]. Thus using CHO-745 cells enables the
elimination of the effect of HS chains on cell fusion. Enhancement
of syndecan-1 on target CHO-K1 and CHO-745 cells resulted in a
significant increase (37.966.9% and 34.569.9% increase respec-
tively P,0.0001) in cell-to-cell fusion compared to wild type cells
that were transfected with GFP control plasmid (Fig. 2B).
Moreover, Syndecan-1 downregulation on target CHO-K1 and
CHO-745 cells inhibited HSV-1 induced cell-to-cell fusion
(41.369.5% and 43.864.3% inhibition respectively P,0.0001)
compared to wild type cells that were transfected with control
scrambled siRNA (Fig. 2C). These results suggest that syndecan-1
may play a role during HSV-1 induced cell-to-cell fusion, and this
role is independent of HS chains.
Enhanced syndecan-1 on effector cells inhibits cell-to-cell
fusion
The fusion of the virus envelope with the host cell plasma
membrane results in the expression of the virus glycoproteins on
the surface of the infected cell along with the cell membrane
proteins including syndecan-1. To understand the effect of
increase in syndecan-1 level with the virus glycoproteins on the
same cell, we overexpressed syndecan-1 on the effector cell
population that also expresses HSV-1 fusion glycoproteins.
Interestingly, syndecan-1 overexpression on effector CHO-K1
and CHO-745 cells inhibited HSV-1 induced cell-to-cell fusion
significantly compared to wild type cells that were transfected with
GFP control plasmid (P,0.0001) (Fig. 2D). This result was
observed in CHO-K1 cells (43.666.0% inhibition) as well as
CHO-745 cells (36.4617.5% inhibition) that lack all GAGs
Syndecan-1 in HSV-1 Spread
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independent.
Enhancement of syndecan-1 production in target cells
induces the syncytial cell formation, whereas the same
on effector cells inhibits syncytial cell formation and
reduces the average number of nuclei per syncytia
HSV-1 induced cell-to-cell fusion results in the formation of
large, multinucleated syncytial cells [8]. To compare the number
and size of syncytia after overexpressing syndecan-1 on target or
effector cells, a cyan fluorescent protein (CFP) construct attached
to a nuclear localization signal (NLS) for limiting the CFP to
the nuclei was additionally transfected into target cells. Likewise,
the effector cells were also additionally transfected with a red
fluorescent protein (RFP) attached to a nuclear export signal
(NES), limiting the expression of RFP to the cytoplasm [26,32].
Syncytia were then identified as cells expressing red cytoplasm and
at least one blue nucleus (Fig. 3A). The top panels show
representative syncytia formed in CHO-K1 cells after overex-
pressing syndecan-1 on target or effector cells. The bottom panels
show representative syncytia formed in CHO-745 cells after
overexpressing syndecan-1 on target or effector cells. The positive
controls consist of target cells mixed with effector cells where both
populations express normal levels of syndecan-1. The negative
controls consist of target cells mixed with effector cells missing gB,
and thus no syncytia formation (Fig. 3B).
Table 1 lists the average number of syncytia formed in CHO-
K1 and CHO-745 cells in each condition and the size of syncytia
formed indicated by the average number of syncytia that had 2
nuclei, 3–5 nuclei, or more than 5 nuclei. Table 1 shows that
overexpressing syndecan-1 on target CHO-K1 or CHO-745 cells
formed a significantly greater number of syncytia than the positive
control that has target and effector cells expressing normal levels of
Figure 1. Syndecan-1 knockdown or overexpression do not affect cell viability. (A). CHO-K1, CHO-745, and HCE cells were transfected with
scrambled (scr) siRNA or syndecan-1 (SDC1) siRNA. 72–96 h after transfection, immunoblots of cell lysates were prepared and probed with anti-SDC1
polyclonal Ab. b-actin protein level was measured as loading control. Representative blots are shown. Protein bands were quantified using
ImageQuant TL image analysis software (version: 7). SDC1 protein expression (mean 6 1SD), normalized to that of b-actin, of at least three
independent experiments was quantified by calculating the relative intensity of each syndecan-1 band relative to the control scrambled siRNA
treated bands, and presented as bar graph. (B) Cells were grown in 6-well plates, mock treated or transfected with human SDC1 plasmid for 48 h. Cell
surface level of SDC1 was evaluated by flowcytomety. FITC stained cells were used as background control. Results are representative of two
independent experiments (C, D). Cells were grown in 96-well plates, transfected with scrambled siRNA or SDC1 siRNA for 48 h (C), or transfected with
control GFP plasmid or human SDC1 plasmid for 24 h (D). Triplicate wells were evaluated for cell viability using MTS assay. Results are expressed as
100% wild type (wt) viability where they represent the percent corrected absorbance after subtracting the background absorbance, relative to
scrambled siRNA transfected cells (C), or relative to GFP transfected cells (D), and are mean 6 1SD of at least 2 independent experiments.
doi:10.1371/journal.pone.0025252.g001
Syndecan-1 in HSV-1 Spread
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e25252syndecan-1(P,0.05). However, overexpressing syndecan-1 on
effector CHO-K1 or CHO-745 cells formed a significantly smaller
number of syncytia compared to the positive control (P,0.05).
The number of nuclei per syncytia cell was also examined.
Overexpressing syndecan-1 on target cells did not result in a
significant increase in the number of nuclei per syncytial cell.
However, when syndecan-1 was overexpressed on effector cells,
syncytia formed had significantly fewer nuclei per syncytial cell
(P,0.05).
The ectodomain and the cytoplasmic domains of
syndecan-1 are important for inhibiting HSV-1 induced
cell-to-cell fusion when syndecan-1 co-exists with HSV-1
glycoproteins on effector cells
To determine whether specific syndecan-1 domain(s) are required
for the observed inhibition of HSV-1 induced cell-to-cell fusion when
syndecan-1 is overexpressed on the effector cells along with HSV-1
fusion glycoproteins, a series of syndecan-1 molecules with specific
truncations and mutations were expressed and analyzed. A diagram
summarizing the mutant constructs used is shown in Fig. 4A. Cell
fusion assay after overexpressing syndecan-1 mutants reveals
that while the constructs FcR
ecto-hS1 (a construct in which the
ectodomain of syndecan-1 is replaced by that of the human Fc) and
hS1
Dcyto (aconstructthatlackingthe33C-terminalaminoacids)were
able to allow the fusion to near positive control levels that express
normal levels of syndecan-1, overexpressing the construct hS1
pLeuTM
(a construct in which the transmembrane domain is replaced with
leucine residues) on effector cells resulted in similar inhibition of
HSV-1 induced cell fusion caused by overexpressing the wild type
syndecan-1 (Fig. 4C). The cell surface expression of syndecan-1
mutants has been confirmed previously [33]. These results were
observed in both CHO-K1 and CHO-745 cell lines, and were not
due to cytotoxic effect of overexpressing syndecan-1 mutants, as that
Figure 2. Syndecan-1 overexpression on target cells enhances cell fusion, while its overexpression on effector cells inhibits cell
fusion. (A). An illustration of cell fusion assay that was exploited to understand the contribution of syndecan-1 during HSV-1 induced cell-to-cell
fusion. Effector cell population that expresses HSV-1 fusion glycoproteins plus T7 polymerase is mixed with the target cell population that expresses
nectin-1 as a gD receptor and the luciferase reporter gene under the control of T7 promoter. Luciferase reporter gene activity is determined to
quantify cell-to-cell fusion. (B). Target cells for CHO-K1 and CHO-745 cells were either transfected with GFP control plasmid (wild type cells) or
transfected with syndecan-1 plasmid and mixed with effector cells 24 h post-transfection. As a negative control, target cells were mixed with effector
cells that lack HSV-1 gB (C). Target cells for CHO-K1 and CHO-745 cells were either mock treated (wild type cells) or transfected with syndecan-1
specific siRNA and mixed with effecor cells 48 h post-transfection. As a negative control, target cells were mixed with effector cells that lack HSV-1 gB.
(D). Effector cells for CHO-K1 and CHO-745 cells were transfected with either GFP control plasmid (wild type cells) or human syndecan-1 plasmid and
mixed with target cells 24 h post-transfection. As a negative control, target cells were mixed with effector cells that lack HSV-1 gB. (B, C, D). Fusion
was measured 16 h post mixing. Results are presented as mean 6 1 SD of at least 3 independent experiments. SDC1, syndecan-1.
doi:10.1371/journal.pone.0025252.g002
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results demonstrate that syndecan-1 ectodomain and cytoplasmic
domains but not the transmembrane domain are required for
reduced cell fusion when syndecan-1 is overexpressed along with
HSV-1 fusion glycoproteins on effector cells.
Syndecan-1 knockdown reduces plaque formation in
HCE cells
HSV-1 has the ability to produce visible plaques on HSV-1
susceptible cells which results in central clearing as the virus
spreads [34]. One way of its spread is lateral virus cell-to-cell
spread by the fusion of infected cells with neighboring uninfected
cells to form large multinucleated syncytial cells that can then
slough off forming plaques. HCE cells were chosen to examine the
contribution of syndecan-1 during HSV-1 plaque formation
because corneal epithelium represents one of the major infection
sites for HSV-1 and may precede infection of other parts within
the eye [28]. Plaquing efficiency of HSV-1 was examined in HCE
cells after either overexpressing or downregulating syndecan-1.
Confluent monolayers of HCE overexpressing syndecan-1, or
have syndecan-1 downregulated were infected with serial dilutions
of virus stocks and overlaid with 0.5% methylcellulose growth
Figure 3. Syncytial cell formation in CHO-K1 and CHO-745 after syndecan-1 overexpression. (A). An illustration of syncytia assay that was
exploited to understand the contribution of syndecan-1 during HSV-1 induced cell-to-cell fusion. Effector cell population that expresses HSV-1 fusion
glycoproteins, T7 polymerase as well as a RFP-NES construct that restricts the expression of RFP to the cytoplasm is mixed with the target cell
population that expresses nectin-1 as a gD receptor, the luciferase reporter gene under the control of T7 promoter as well as a CFP-NLS construct that
restricts the level of CFP to the nucleus. (B). Syncytia formation was observed in cells 72 h after the mix of target cells with effector cells. Top panels
show representative syncytia formed in CHO-K1 cells after overexpressing syndecan-1 in target, or effector cell. Bottom panels show representative
syncytia formed in CHO-745 cells after overexpressing syndecan-1 in target, or effector cells. Positive controls are target cells mixed with effector cells
where both populations have the wild-type level of syndecan-1 on the surface. Negative controls are target cells mixed with effector cells missing gB.
(Scale bar=37.5 mm). SDC1, syndecan-1.
doi:10.1371/journal.pone.0025252.g003










CHO-K1 Positive control 142.569.8 30613.9 63614.6 50.88616.5
SDC1 on targets 196.8615.0 6667 72.7622.0 49.6616.7
SDC1 on effectors 72.8619.3 43.3624.9 22.266.5 4.565.7
CHO-745 Positive control 213.864.6 38.5617.0 89.563.5 85.8625.1
SDC1 on targets 338.3613.8 129.366.7 131.368.8 77.8615.9
SDC1 on effectors 46.868.8 17.361.8 23.564.9 665.7
Average number of syncytial cells, as well as, the average number of nuclei per syncytia was counted in CHO-K1 and CHO-745 cells after overexpressing syndecan-1 on
target cells or effector cells. Positive controls are target and effector cells expressing normal levels of syndecan-1. Syncytial cells were counted 72 h post mixing. Syncytia
were classified as any red cell having two or more nuclei. Number of syncytia was normalized to the number of syncytia detected in the negative control wells where
the effector cell population lacks gB. The average is based on results from two independent experiment performed in duplicate (mean 6 1SD).
doi:10.1371/journal.pone.0025252.t001
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and stained and plaques were counted. Surprisingly, the number
of plaques formed after syndecan-1 overexpression on HCE cells
resulted in an insignificant reduction in plaque formation.
However, as seen with cell fusion assay, the downregulation of
syndecan-1 resulted in 57.3763.96 % reduction in plaques
formation (p,0.0001) (Fig. 5B). Overexpressing syndecan-1
mutants did not show significant difference in plaque number.
However one mutant showed smaller plaque size.
Increase in syndecan-1 production increases plaque size,
while a reduction in its expression and overexpression of
a syndecan-1 mutant that lacks the ectodomain form
smaller size plaques
To further investigate the role of syndecan-1 in lateral HSV-1
transmission, plaque size was examined after overexpressing wild
type syndecan-1 and syndecan-1 mutants, or downregulating
syndecan-1 in HCE cells. As demonstrated in Fig. 6A, the average
plaque size formed in HCE cells after syndecan-1 overexpression
was larger than that of the positive control HCE cells that express
normal levels of syndecan-1 (16.19%61.13, P,0.05), showing that
wild type syndecan-1 induced lateral virus spread, confirming the
cell fusion results where enhancement of syndecan-1 production
showed increase in cell fusion which is one major way the virus
can laterally spread (Fig. 6A). Interestingly, overexpressing
the mutant FcR
ecto-hS1 that lacks the ectodomain of syndecan-1
showed smaller size plaques compared to the positive control
(17.16%66.54, P=0.065) indicating that the ectodomain of
syndecan-1 might play a role in the virus lateral spread (Fig. 6A).
Representative plaques from each condition are shown in Fig. 6A.
Since the increase insyndecan-1 resulted in larger size plaques, the
effect of syndecan-1 loss on plaque size was examined. Syndecan-1
Figure 4. syndecan-1 ectodomain and cytoplasmic domains are important for inhibiting cell fusion when overexpressed on effector
cells. (A). Syndecan-1 truncation and mutants used in the study are illustrated including the full-length wild type (wt) core protein syndecan-1 (SDC1)
that includes an extracellular domain, transmembrane domain (TM), and COOH-terminal cytoplasmic domain. Also illustrated are the construct
FcR
ectohS1 that is a chimera comprised of the ectodomain of human IgG Fcc receptor Ia/CD64 fused to the transmembrane and cytoplasmic domains
of human syndecan-1, the construct hS1
pLeuTM that has the transmembrane domain replaced with leucine residues, and a truncation mutant hS1
Dcyto
that lacks the 33 C-terminal amino acids. (B) Cells were grown in 96-well plates, transfected with control GFP plasmid, full-length wt human SDC1
plasmid, the construct FcR
ectohS1, the construct hS1
pLeuTM, or the construct hS1
Dcyto for 24 h. Triplicate wells were evaluated for cell viability using
MTS assay. Results are expressed as 100% wild type (wt) viability where they represent the percent corrected absorbance after subtracting the
background absorbance, relative to control GFP plasmid transfected cells, and are mean 6 1SD of at least 3 independent experiments. (C). Effector
cells for CHO-K1 and CHO-745 cells were transfected with either control GFP plasmid, full-length wt syndecan-1, the construct FcR
ectohS1, the
construct hS1
pLeuTM, or the construct hS1
Dcyto and mixed with the target cells 24 h post-transfection. Fusion was measured 16 h post mixing. Results
are presented as mean 6 1 SD of at least 3 independent experiments. As a negative control, target cells were mixed with effector cells lacking HSV-1
gB.
doi:10.1371/journal.pone.0025252.g004
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compared with HCE cells transfected with the control scrambled
siRNA supporting the involvement of syndecan-1 in HSV-1 lateral
cell-to-cell spread (Fig 6B). Representative plaques from each
condition are shown in Fig 6B.
Syndecan-1 downregulation reduces HSV-1 spread
Since syndecan-1 downregulation showed significantly smaller
plaque size compared to control cells transfected with scrambled
siRNA, we aimed to confirm the involvement of syndecan-1 in
virus lateral cell-to-cell spread by performing virus spread assay.
HSV-1(KOS) infected HCE cells, which were treated with low pH
citrate buffer to inactivate residual virus, were mixed with
syndecan-1 siRNA transfected cells, and the virus spread was
evaluated by counting the number of plaques formed 48–72 h post
mixing. Syndecan-1 knockdown resulted in less virus spread
compared to HCE cells transfected with scrambled siRNA
(26.9364.62, P,0.0001) (Fig. 7A). A qualitative fluorescent
approach was also utilized to examine the effect of syndecan-1
downregulation on virus spread. HSV-1 (KOS) K26GFP virus
strain that has the jellyfish green fluorescent protein (GFP) fused in
frame with the UL35 open reading frame generating K26GFP
virus whose capsids express GFP [35] was used in the spread assay
(Fig.7B). The top panels show representative HSV-1 (KOS)
K26GFP virus spread to HCE cells treated with either syndecan-1
siRNA or the control scrambled siRNA. Syndecan-1 downregu-
lation resulted in less virus spread as indicated by the less green
fluorescence compared to control scrambled siRNA transfected
cells. The bottom panels show HCE cells under the bright field.
Together these results strengthen the conclusion that syndecan-1 is
involved in HSV-1 lateral cell-to-cell spread.
Syndecan-1 downregulation reduces infectious virus
production
Since knocking down syndecan-1 on HCE cells resulted in
reducing the plaquing efficiency of HSV-1, we sought to verify
whether this reduction also translates into a loss of infectious
virus produced as well. To answer this question, infectious virus
production was analyzed after syndecan-1 downregulation. HCE
cells transfected with either scrambled siRNA or syndecan-1
specific siRNA were infected 72 h post-transfection with HSV-1
(KOS) at an MOI of 0.1. At various times post-infection, cells and
media were harvested, and virus titers were measured. Consistent
with the results of plaquing efficiency, the downregulation of
syndecan-1 severely impaired infectious virus production (P,0.05)
(Fig. 8). Taken together, these results suggest that downregulation
of syndecan-1 also negatively impacts infectious virus production.
Discussion
HSV-1 entry into host cell starts with the attachment of HSV-1
gB and gC with HSPG on the surface of the host cell. While
substantial work has focused on delineating the role of HS as an
attachment receptor for HSV-1, far less is known about the
contribution of the HSPG core protein in HSV-1 infection. Our
study demonstrates a novel role for the core protein of HSPG
during HSV-1 infection. Specifically, we demonstrate that the core
protein of syndecan-1 contributes to HSV-1 induced cell-to-cell
fusion and lateral spread and those functions are independent of
HS chains. The increase of syndecan-1 in target cells enhanced
HSV-1 induced cell-to-cell fusion, while its decrease reduced cell
fusion as well as virus spread.
A related interesting finding of our study is that the
overexpression of syndecan-1 in effector cells that express HSV-
1 fusion glycoproteins (gD, gB, gH, and gL) showed significantly
reduced HSV-1 induced cell-to-cell fusion. The observed reduc-
tion in cell-to-cell fusion is reminiscent of a previously described
phenomenon called gD-mediated interference, where expressing
gD in HSV-1 susceptible cells results in resistance to viral entry
due to sequestering gD receptors and preventing their accessibility
by cell-associated gD [19,36]. This raises the possibility that there
might be a direct interaction between syndecan-1 and at least one
of the fusion glycoproteins, which in turn sequester at least one of
the glycoproteins preventing them from being fully functional
during cell-to-cell fusion. Our results showed similar levels of
inhibition of cell-to-cell fusion in both CHO-K1 and CHO-745
cells. The latter differ from CHO-K1 cells in that CHO-745 cells
are deficient in the synthesis of all GAGs [30,31]. This suggests
that this inhibition in cell-to-cell fusion is HS independent and not
due to interactions between HS and HSV-1 fusion glycoproteins,
since it is well known that gB utilizes HS chains on HSPGs as an
attachment receptor to initiate the entry process of the virus into
the host cell [8].
Figure 5. Syndecan-1 knockdown reduces plaque formation in
HCE cells. (A). Monolayers of HCE cells were transfected with either
control plasmid GFP, or with human syndecan-1. 24 h post-transfection
cells were infected with serial dilution of HSV-1(KOS) stocks. (B). 50%
confluent HCE cells were transfected with either control scrambled
siRNA or syndecan-1 specific siRNA. 72 h post-transfection, cells were
infected with serial dilution of HSV-1(KOS) stocks. (A, B). 72 h post-
infection cells were fixed and stained with crystal violet stain. Infectivity
was measured by the number of plaque forming units (PFUs). Number
of PFUs was counted at the 106objective (Zeiss Axiovert 200). Plaques
consist of 15 or more nuclei were counted. Results are means 6 1S Do f
three independent experiments conducted in duplicate. SDC1, synde-
can-1.
doi:10.1371/journal.pone.0025252.g005
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physically binding other cellular protein(s) that HSV-1 glycopro-
tein(s) require for fusion. This binding could also prevent the
cellular protein from interacting with HSV-1 fusion glycoproteins,
and that somehow leads to less efficient cell-to-cell fusion.
Syndecan-1 ectodomain and cytoplasmic domain, which our
results indicate their importance in this phenomenon, are both
been shown to interact with a wide range of cellular proteins [37].
For example syndecan-1 ectodomain has been shown to interact
directly with b3o rb5 integrins, which in turn have been shown to
be cellular determinants of HSV-1 rout of entry [38,39]. It is also
possible that overexpressing syndecan-1 along with HSV-1 fusion
glycoproteins may perturb cellular signaling mechanisms required
for efficient cell-to-cell fusion. The core protein of syndecan-1
functions in a variety of signaling pathways that are involved in
regulatory events, like actin cytoskeleton reorganization, cell
adhesion, cell proliferation, and angiogenesis, many of which are
involved in HSV-1 infection [26,40–48]. Further work will be
critical to clearly understand the reason behind the reduced cell-
to-cell fusion upon syndecan-1 overexpressing along with HSV-1
fusion glycoproteins in effector cells.
This study also demonstrates that syndecan-1 is involved in
HSV-19s ability to form plaques. Although syndecan-1 overex-
pression did not result in increased number of plaques, the
knockdown of syndecan-1 resulted in significant impairment in
plaques formation. One possible explanation is that syndecan-1
might be a regulatory component of a multi-protein complex that
affects virus plaque formation. In that case, loss of syndecan-1, and
not so much the extra copies of syndecan-1, is critical for cell-to-
cell fusion. It is also possible that for this multi-protein complex,
over-expression of syndecan-1 alone may not lead to more
complex formation since the other components of that complex
are not overexpressed. Another explanation is that syndecan-1 is
involved in signaling pathways important for virus plaque
formation, so a reduction in syndecan-1 level resulted in less
efficient plaque formation, but an enhancement in syndecan-1
production did not affect the virus’s ability to form plaques.
Although the overexpression of syndecan-1 did not result in
more efficient plaque forming ability of HSV-1, it did, however,
result in plaques with bigger sizes. By the same token, the
knockdown of syndecan-1 resulted in smaller size plaques
compared to control siRNA transfected cells. The plaque assays
were preformed in the presence of methylcellulose layer where
plaque formation depended exclusively on cell-to-cell virus spread.
This suggests that syndecan-1 is playing a key role during HSV-1
virus spread. This suggestion was strengthen by a spread assay
where the knockdown resulted in less virus spread as evident by a
quantitative and a qualitative spread assays.
We further analyzed the effect of syndecan-1 knockdown on
infectious virus titers after HSV-1 (KOS) infection utilizing HSV-1
growth curve assay. Syndecan-1 knockdown severely reduced the
titers of infectious virus. The effect of syndecan-1 downregulation
Figure 6. Effect of syndecan-1 overexpression, or downreguulation on HSV-1 plaque size. Monolayers of HCE cells were transfected with
either control GFP plasmid, full-length wt syndecan-1 (SDC1), or the construct FcR
ectohS1. 24 h post-transfection, cells were infected with HSV-1 (KOS)
at an MOI of 0.1 and overlaid with 0.5% methylcellulose medium. (B) 50% confluent HCE cells were transfected with either control scrambled siRNA or
syndecan-1 sprecific siRNA. 72 h post-transfection, cells were infected with HSV-1 (KOS) at an MOI of 0.1 and overlaid with 0.5% methylcellulose
medium. (A, B). 72 h post-infection cells were fixed and stained using rabbit anti-HSV-1, horseradish peroxidase-conjugated secondary antibody, and
3,39-diaminobenzidine tetrahydrochloride (DAB) substrate. Plaques were measured with a micrometer at the 106objective (Zeiss Axiovert 200), and
the area was calculated by measuring the outline of each plaque using Axioversion software (version 4). Results are expressed as relative plaque size
(means 6 1 SD) of two independent experiments conducted in duplicate. Representative plaques from each condition are shown. SDC1, syndecan-1.
doi:10.1371/journal.pone.0025252.g006
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syndecan-1 playing role in HSV-1 induced cell fusion, HSV-1
spread and its role in virus entry suggested by our lab and others
[10,11]. However, this does not exclude the possibility that at least
part of this observed reduction in HSV-1 growth curve might be
due to less HSV-1 replication in HCE cells transfected with
syndecan-1 siRNA.
Further studies must be done to determine the molecular
mechanisms behind the contribution of syndecan-1 during HSV-1
infection. The emerging role of syndecan-1 during HSV-1
infection opens new doors that might add clarity to the picture
of virus entry and infection. The role of syndecan-1 has been
investigated during other virus infections including Kaposi’s
sarcoma-associated herpesvirus [49,50], human papillomaviruses
[51], and human immunodeficiency virus (HIV) infection, where,
in the case of HIV infection, syndecan-1 has been shown to be
involved in capturing and transmitting the virus to permissive cells
[52]. Delineating the role of syndecan-1 during the various HSV-1
infection events, especially those at the early stages of the infection
is of significance as that might help the development of new
antiviral agents or an effective HSV-1 vaccine.
Materials and Methods
Cell culture and viruses
Wild type Chinese hamster ovarian (CHO-K1) cells, mutant
CHO-745 cells, and Vero cells were provided by P. G. Spear
(Northwestern University). The human corneal epithelial (HCE)
cell line (RCB1834 HCE-T) was provided by Dr. Kozaburo
Hayashi (National Eye Institute, Bethesda, MD) [53]. All CHO
cell lines were grown in Ham’s F-12 medium (Gibco/BRL,
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum
(FBS) and penicillin and streptomycin (P/S) (Sigma). Vero cells
were grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% FBS and P/S. HCE cells were grown in
minimum essential medium (MEM) supplemented with 10% FBS
and P/S. Wild type HSV-1 (KOS) virus strain was provided by
P.G. Spear (Northwestern University). HSV-1 (KOS) K26GFP
virus strain was provided by P. Desai (the Johns Hopkins
Universiy) Jellyfish green fluorescent protein (GFP) was fused in
frame with the UL35 open reading frame generating K26GFP
virus whose capsids express GFP [35]. Virus stocks were
propagated and titered on Vero cells, and stored at280uC.
Plasmids and Antibodies
HSV-1 (KOS) glycoproteins expressing plasmids used were
pPEP98 (gB), pPEP99 (gD), pPEP100 (gH), and pPEP101 (gL)
[54]. Wild type human syndecan-1 (SDC1) and human syndecan-
1 mutants including FcR
ectohS1 (a chimera comprised of the
ectodomain of human IgG Fcc receptor Ia/CD64 fused to the
transmembrane and cytoplasmic domains of human SDC1),
hS1
Dcyto (lacking the 33 C-terminal amino acids) and hS1
pLeuTM
(transmembrane domain replaced with leucine residues) were
provided by Alan Rapraeger (University of Wisconsin-Madison)
[55]. The following antibodies were used for this study: Rabbit
anti-syndecan-1 polyclonal antibody (Ab) diluted 1:500 (sc-5632
Santa Cruz Biotechnology, Santa Cruz, CA); mouse anti-b-actin
monoclonal Ab (mAb) at 1:1000 dilution (A-5316 Sigma-Aldrich);
mouse anti-syndecan-1 mAbs at 1 mg per 1610
6 cells dilution
(Santa Cruz Biotechnology). Secondary Abs for Western blots
were horseradish peroxidase-conjugated goat anti-rabbit IgG
diluted 1:20000 (73102, Jackson ImmunoResearch Laboratories,
West Grove, PA); and horseradish peroxidase-conjugated anti-
mouse IgG diluted 1:25000 (115-035-062, Jackson ImmunoR-
esearch Laboratories). Secondary Ab for flow cytometry was
FITC-conjugated anti-mouse secondary antibody diluted 1:100
(Sigma-Aldrich).
siRNA and DNA plasmid Transfections
For human syndecan-1 (accession number NM_002997) knock-
down experiments, two siRNAs generated with 39-dTdT over-
hangs and prepared by Sigma, were chosen against the DNA
target sequences as follows: (59-CCATTCTGACTCGGTTTCT-
39,5 9-GCCAAGGTTTTATAAGGCT-39). siRNA cell transfec-
tion was performed using Lipofectamin 2000 reagent (Invitrogen,
Cergy Pontoise, France) with 200 nM duplex siRNA according to
the manufacturer’s recommendations. In all experiments, cells
were analyzed 72 h after transfection. A nonspecific scrambled
siRNA (GAUCAUACGUGCGAUCAGA) was used as a negative
control (Sigma). For DNA plasmid transfection, cells were grown
Figure 7. Syndecan-1 downregulation reduces HSV-1 spread.
Monolayers of HCE cells were exposed to (A) HSV-1 (KOS) or (B) HSV-1
(KOS) K26GFP strains at MOI of 5 at 37uC to allow virus entry. 2 h post-
infection, cells were washed, incubated for 1 min with 0.1 M citrate
buffer (PH 3.0), then washed with PBS and overlaid with 0.5%
methylcellulose medium. After 4 h, cells were washed, dissociated,
and approximately 600 cells were plated onto 80% confluent
monolayers of uninfected HCE cells that have been transfected with
either scrambled siRNA or syndecan-1 siRNA for 72 h in 0.5%
methylcellulose medium. (A). The spread of HSV-1 (KOS) from infected
cells to the siRNA transfected HCE cells was evaluated by staining and
counting the number of plaques formed at the 106 objective (Zeiss
Axiovert 200). Results are presented as relative number of plaques
(mean 6 1SD) of four independent experiments performed in
duplicates. (B) HSV-1 (KOS) K26GFP spread was qualitatively assessed
at the 106objective (Zeiss Axiovert 200). Representative images from
one experiment performed in triplicate are shown. SDC1, syndecan-1.
doi:10.1371/journal.pone.0025252.g007
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according to the manufacturer’s recommendations.
Immunoblotting
72 h post-transfection with syndecan-1 siRNA, or scrambled
siRNA, syndecan-1 protein expression was determined by Western
blot analysis. The Western blot assay was performed according to
protocols described previously [56]. Briefly, Whole cell lysates of
the siRNA-transfected cells were denatured in NuPAGE LDS
Sample Buffer (Invitrogen, NP0007) and heated to 86uC for 8 min
before gel loading. Equal amounts of protein were subjected to 4–
12% SDS-PAGE and electroblotted onto a nitrocellulose mem-
brane. Nonspecific binding was blocked using 5% nonfat milk in
tris buffered saline (TBS) for 2 hours at 37uC. The membranes
were then incubated with primary rabbit polyclonal antibodies
(Santa Cruz) to sydecan-1 at 1:500 dilutions overnight at 4uC. The
blots were rinsed 5 times with 0.1% TTBS (0.1% Tween 20 in
TBS) for 5 min followed by incubation for 1 h at room
temperature with horseradish peroxidase-conjugated anti-rabbit
IgG (Promega, 1:20000). Protein bands were detected using
SuperSignal West Femto maximum sensitivity substrate (Pierce,
34096), and visualized using ImageQuant LAS 4000 imager (GE
Healthcare Life Sciences). Protein bands were quantified using
ImageQuant TL image analysis software (version: 7). For repeated
probing, the blots were stripped for 30 min at room temperature
with Restore
TM Western Blot stripping buffer (Thermo scienctific,
21059). b-actin was measured as a loading control. Syndecan-1
was quantified by calculating the relative intensity of each
syndecan-1 band to that of b-actin.
Flow cytometry
Syndecan-1 cell surface expression was detected after syndecan-
1 transfection in CHO-K1, CHO-745, and HCE cells. Confluent
monolayer of cells were either mock treated or transfected with
human syndecan-1 plasmid for 48 h. Cells were then washed with
PBS, harvested, and incubated with syndecan-1 primary antibody
at 1 mg per 1610
6 cells diluted in PBS with 1% BSA for 1 h at
4uC. After primary antibody incubation, cells were washed and
incubated for 30 min with anti-mouse-FITC-conjugated second-
ary anti-IgGs (1:100). Cells stained only with anti-mouse-FITC
were used as background control.
Cytotoxicity assays
For cytotoxicity studies after syndecan-1 and syndecan-1
mutants overexpression, 2.5610
4 cells/well were plated in 96-
well plates and tranfected with full-length wt syndecan-1, the
construct FcR
ectohS1, the construct hS1
Dcyto, the construct
hS1
pLeuTM or control GFP plasmid. For cytotoxicity studies after
syndecan-1 knockdown, 1610
4 cells/well were plated in 96-well
plates and tranfected with syndecan-1 siRNA, or scrambled
siRNA. After 6 h of transfection, serum-enriched medium was
added and cultures were followed for 24 h after overexpressing
syndecan-1 and 72 h after downregulating syndecan-1. Cell
viability was evaluated by a chromogenic kit (CellTiter AQue-
ous96; Promega, Madison, WI, USA) and colorimetric detections
were performed using microplate ELISA reader (Spectra Max 190
Molecular Devices, Sunnydale, CA USA). Results were expressed
as 100% wild type (wt) viability where they represent the percent
corrected absorbance after subtracting the background absor-
bance, relative to GFP transfected cells in syndecan-1 overexpres-
sion experiments, or relative to scrambled siRNA transfected cells
in syndecan-1 downregulation experiments.
Cell-to-Cell Fusion Assays
Standard cell-to-cell fusion assay was used as previously
described [30,57]. Cells were split into two populations. ‘‘Target’’
cells were transfected with plasmid expressing Nectin-1 as a gD
receptor (1.0 mg) and the luciferase gene (0.5 mg). ‘‘Effector’’ cells
were transfected with plasmids expressing HSV-1 glycoproteins
gD, gB, gH, and gL and T7 RNA polymerase (0.5 mg each). For
cell fusion experiment after syndecan-1 overexpression, target or
effector cells were additionally transfected with 0.5 mg of a plasmid
expressing human syndecan-1 or control green fluorescent protein
(GFP) plasmid. For cell fusion experiment after syndecan-1
Figure 8. Downregulation of Syndecan-1 results in reduced production of infectious virus. HCE cells were transfected with either control
scrambled siRNA or syndecan-1 siRNA. 72 h post-transfection cells were infected with HSV-1 (KOS) at an MOI of 0.1. At 0, 5, 24, 48, and 72 h post-
infection, infectious virus was quantified by a standard plaque assay on HCE cell monolayers. The titers shown are the mean 6 1S Do fa
representative experiment of two independent experiments performed in duplicates. SDC1, syndecan-1.
doi:10.1371/journal.pone.0025252.g008
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transfected with syndecan-1 siRNA. After 24 h, target and effector
cells were transfected as described above. After 16 h, target and
effector cells were mixed in a 1:1 ratio and replated in 24-well
dishes. Luciferase activity was measured after 16 h. As a negative
control, target cells were mixed with effector cells that lack HSV-
1 gB.
Syncytia Assay
Assay was performed as previously described [26]. Target
cells were additionally transfected with 0.5 mgo fap l a s m i d
expressing cyan fluorescent protein (CFP) fused to a nuclear
localization signal (NLS) (Clontech, Mountain View, CA).
Effector cells were also transfected with a red fluorescent
protein (RFP)-expressing plasmid fused to a nuclear export
signal (NES) [32]. Target and effector cells were mixed in a 1:1
ratio and replated in 8-chamber slides (Lab-Tek Corp.).
Syncytia images were captured after 72 h using microscopy at
the 406 objective on a confocal microscope (Leica DMIRE2)
equipped with a camera (Leica TCSSP2). Syncytia size and
number were compared after 72 h at the 106 objective (Zeiss
Axiovert 200). Number of syncytia was normalized to the
number of syncytia detected in the negative control wells where
the effector cell population lacks gB.
Virus growth assays
Plaque assays. Monolayer of HCE cells in 24 well plates
overexpressing syndecan-1, syndecan-1 mutants, or GFP control
plasmid (0.8 mg using Lipofectamine 2000 reagent), or transfected
with syndecan-1 siRNA, or scrambled siRNA, as described
above, were infected with 10-fold serial dilutions of HSV-1 (KOS)
virus stocks. Infected cells were fixed with methanol, stained with
crystal violet, and plaques were counted at the 106 objective
(Zeiss Axiovert 200).
Plaque size determination. Monolayer of HCE cells in 4-
well chamber slides (Lab-Tek Corp.) overexpressing syndecan-1,
syndecan-1 mutants, or GFP control plasmid, or monolayer of
HCE cells in 24-well plate transfected with syndecan-1 siRNA, or
scrambled siRNA, were infected with 0.1 MOI of HSV-1 (KOS).
After 2 h of adsorption at 37uC, inoculums were removed; cells
were washed twice with PBS. Infected cells were overlaid with
0.5% methylcellulose (sigma). The overlay was removed at 3 dpi,
and cells were fixed with a 1:1 dilution of methanol:acetone, or
100% methanol. Plaques were stained using rabbit anti-HSV-1
(Dako), horseradish peroxidase-conjugated secondary antibody
(Amersham), and 3, 39-diaminobenzidine tetrahydrochloride
(DAB) substrate (Sigma). Plaques were measured with a
micrometer at the 106 objective (Zeiss Axiovert 200), and the
area was calculated by measuring the outline of each plaque using
Axioversion software (version 4). The average area was
determined by measuring 22 plaques from each of the two
experiments performed in duplicate.
Growth curves. Monolayers of HCE cells in 6 well plate
transfected with syndecan-1 siRNA, or scrambled siRNA, were
infected with HSV-1 (KOS) at a multiplicity of infection (MOI) of
0.1. After 2 h of adsorption at 37uC, inoculums were removed,
cells were washed twice with Hanks’ balanced salt solution, and
growth medium was added back to each culture. 1, 5, 24, 48, and
72 h post-infection, cells were scraped into medium, and cell
suspensions were transferred to tubes, sonicated, clarified by
centrifugation (8006 g for 10 min), and stored at 280uC.
Infectious virus in the supernatant was quantified by standard
plaque assay on HCE cell monolayers.
Virus spread Assay
Virus spread assay was designed using previously described
protocols [58,59]. Monolayer of HCE cells were exposed to HSV-
1 (KOS) or HSV-1 (KOS) K26GFP strains at MOI of 5, at 37uC
to allow virus entry. 2 h post-infection, cells were washed once
with PBS, and then incubated for 1 min with 0.1 M citrate buffer
(PH 3.0) to inactivate residual virus particles. Cells were then
washed three times with PBS and overlaid with 0.5% methylcel-
lulose (sigma) MEM medium. After 4 h, cells were washed three
times with PBS, and dissociated using Hanks’-based enzyme free
dissociation buffer (Invitrogen). Approximately 600 cells were
plated onto 80% confluent monolayers of uninfected HCE cells
that have been transfected with either scrambled siRNA or
syndecan-1 siRNA for 72 h in 0.5% methylcellulose MEM
medium. The spread of HSV-1(KOS) from infected cells to the
siRNA transfected HCE cells was evaluated by staining and
counting the number of plaques formed at the 106 objectives
(Zeiss Axiovert 200). Whereas the spread of HSV-1 (KOS)
K26GFP from the infected cells to the siRNA transfected HCE
cells was qualitatively assessed by capturing images of the green
virus at the 106objective (Zeiss Axiovert 200).
Statistical analyses
The data shown are the means 6 1SD values. Statistical
analyses were performed with GraphPad Prism software (version
4.0). Data were assessed using unpaired student’s t test. *P,0.05
and **P,0.0001 were regarded as significant differences between
treated and mock-treated groups.
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